





PHARMACEUTICAL 2019

CTI BIOPHARMA CORP
Rank 188 of 363



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 32% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 94%, being 57% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	82,492
Cost of Goods Sold	879
Intangible Assets	0
Liabilities, Current	23,055
Liabilities, Non-Current	13,838
Other Assets	5,547
Other Compr. Net Income	-4,339
Other Expenses	660
Other Liabilities	0
Other Net Income	3,547
Other Revenues	26,290
Property and Equipment	1,793
Research and Development	36,467
Selling, General and Administrative Expense	21,183

Output Variable	Value in 1000 USD
Assets	89,832
Liabilities	36,893
Expenses	59,189
Revenues	26,290
Stockholders Equity	52,939
Net Income	-29,352
Comprehensive Net Income	-31,522
Economic Capital Ratio	94%